Business
Check-Cap Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for its Colorectal Screening Test, C-Scan®
Patients who underwent the procedure, as part of the 2019 U.S. pilot study, were significantly more likely to recommend C-Scan test compared to colonoscopy
About this update from Check-cap Ltd.
[{"type":"text","content":"Patients who underwent the procedure, as part of the 2019 U.S. pilot study, were significantly more likely to recommend C-Scan test compared to colonoscopy\n\n\nISFIYA, Israel, Nov. 22, 2021 /PRNewswire/ -- Check-Cap Ltd. (the \"Company\" or \"Check-Cap\") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the publication of research titled \"Colorectal cancer and polyp detection using a new preparation-free colon-scan capsule: A pilot study of safety and patient satisfaction\" in the peer-reviewed journal Digestive Diseases and Sciences, which further validates C-Scan's safety and patient satisfaction based on data from its 2019 previously completed U.S. pilot study.\nIn this study there were no serious adverse events or occurrences of capsule retention out of the 40 patients who underwent the study procedure. Of the 87% of patients who completed the satisfaction questionnaires, patients were significantly more likely to recommend the C-Scan capsule, with an average score of 4.1 out of 5 versus a 2.8 out of 5 score for colonoscopy (p=0.001).\n\"Screening for the detection of precancerous colorectal polyps is a key approach for cancer prevention. Yet, a known barrier for some patients is the required bowel cleansing for colonoscopy and invasiveness of the procedure. Less invasive alternatives are needed to engage a percentage of the population that avoids regular screening,\" said Seth A. Gross, M.D., principal investigator of the study, gastroenterologist and associate professor of medicine at NYU Langone Health.\nElizabeth Rajan, M.D., principal investigator of the study, gastroenterologist and professor of medicine, Mayo Clinic, Rochester stated, \"Our prospective single-arm pilot study demonstrated positive safety results and high patient satisfaction with a new and unique preparation-free colon capsule system intended for detection of colorectal polyps and masses. This study represents a step forward to a prepless approach for CRC screening that may overcome one of the most important deterrents to screening. A multicenter pivotal study is planned in the U.S. to further validate the performance of this tec...